Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • What does it take to build an inflation proof portfolio in 2026? Business
  • Entrepreneur and Celebrity Trainer Alpha Lucky – The man behind the fastest growing fitness company in UAE Press Release
  • AttainU 100% Placement Guarantee Courses / Money Back Policy: A Unique Program That Gives You the Opportunities of a Lifetime Business
  • A Case Study of Success in Tech, Transline Technologies Limited Technology
  • Kolkata Builds Green: Eco-Friendly Construction at the Core of Urban Renewal Business
  • World Brand Affairs releases the list of Most Trusted Indian Companies in 2023 Business
  • Tesla Picks IPS Academy’s Himanshu Singh for Germany Job, Offers Lucrative ₹4 Crore Package Press Release
  • PSB Manthan 2025: How 7 Bold Moves Will Transform Indian Banking Forever Finance

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

Posted on April 29, 2021 By

ISSAR Pharma, the only company in India which focuses on the research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

Hyderabad (Telangana) [India], April 29: ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides, and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

“We take pride in being India’s first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, the founder of ISSAR. ISSAR’s

FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and a prime focus in Research and Development, ISSAR’s dedicated team of experts is proud to have developed India’s first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Mr. Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients’ quality of life. Before starting ISSAR Pharmaceutical, Mr.Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when Biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with 2 successfully commercialized products, 7 plus patents to his credit, and over 6 commercially viable products under development.

https://issar.co.in/

English, Health, Press Release Tags:ISSARPharma, PeptidebasedNCEs, PNN

Post navigation

Previous Post: Glimpse up the world @worldwithmaria
Next Post: Indian Furniture Rental Industry – Market Size, Growth & Scope

Related Posts

  • A 31-year-old who lived on a chair… until his spine finally said, ‘Enough’ Health
  • Xelate’s Honest Approach Yields Remarkable Success in Job Placements Press Release
  • Celebration of humanity by PP Savani family: 133 fatherless daughters married at mass wedding ceremony Lifestyle
  • Rotary Life – Saving Express Mega Blood Donation Drive Inaugurated By Alok Kansal, Gm – Western Railway Press Release
  • Lords Mark Microbiotech Pvt. Limited receives Mid-Day Health & Wellness Icon Award for Best Preventive Genetic Testing Press Release
  • Metta (Dana) Foundation & Jagriti Dham observed World Diabetes Day & Children’s Day 2025 Health

Recent Posts

  • Fredna Dental Systems Partners with South Korea’s & Introduces BIOTEM AR Implant Technology in India
  • Make Your Financial Plans Easier with a Personal Loan
  • Gohil Group plans G-Farm retail outlets in Ahmedabad and Surat
  • P.C. Chandra Group’s 13th Edition of Jahar Lal Chandra Merit Scholarship Programme
  • Quest Alliance CEO Aakash Sethi Named to TIME100 Next: India, TIME’s Inaugural List of 100 Individuals Defining the Future of India

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Vama Wovenfab Limited Announces Rs. 47.07–Rs. 49.54 Crore SME Initial Public Offering; Issue Opens on Tuesday, 15 September 2026 Business
  • Tariffs, Tough Calls, and Diwali Prep – 1,700 Entrepreneurs Gather in Surat with Strategy on Their Minds Business
  • QX Global Group Named as Leader in the IAOP’s 2024 Global Outsourcing 100 List Business
  • Mukesh Khanna and Shaan Unveil Shiv Tandav in Hindi; Fans Call It a Cultural Milestone Entertainment
  • Aamir Pathan – A social Activist who believes that anyone can change society even by empowering people. English
  • Vishal Mishra to Headline First-Ever Live Concert in Jaipur as Part of “Pehle Bhi Main” India Tour Entertainment
  • Sri Sri Wellbeing reopens its expanded Satellite centre, bringing doctor-led Ayurveda closer to Ahmedabad homes Business
  • Sacred Heart School, Siliguri Redefines Senior Secondary Education with a Future-Ready ISC Program Education

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme